SEC Form 4 · accession 0001193805-18-000820
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam S Grossman
Officer — President and CEO · Director
Period of report
Jun 8, 2018
Accepted (ET)
Jun 11, 2018 · 7:09 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 8, 2018 | P | 20,921 | $4.78 | A | 32,527 | D | |
| Common StockF1,F2 | Jun 8, 2018 | P | 52,301 | $4.78 | A | 796,301 | I | See Footnote |
| Common StockF3 | holding | — | — | — | 580,957 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a purchase from the underwriters in the Issuer's public offering.
- F2These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
- F3These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.